| Title |
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis - Volume 23, Number 10—October 2017 - Emerging Infectious Diseases journal - CDC
|
|---|---|
| Published in |
Emerging Infectious Diseases, October 2017
|
| DOI | 10.3201/eid2310.170303 |
| Pubmed ID | |
| Authors |
Jay Achar, Cathy Hewison, Ana P. Cavalheiro, Alena Skrahina, Junia Cajazeiro, Parpieva Nargiza, Krzysztof Herboczek, Assliddin S. Rajabov, Jennifer Hughes, Gabriella Ferlazzo, James A. Seddon, Philipp du Cros |
| Abstract |
We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited. |
X Demographics
The data shown below were collected from the profiles of 29 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 4 | 14% |
| United States | 4 | 14% |
| United Kingdom | 2 | 7% |
| Canada | 1 | 3% |
| India | 1 | 3% |
| Spain | 1 | 3% |
| Unknown | 16 | 55% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 21 | 72% |
| Practitioners (doctors, other healthcare professionals) | 5 | 17% |
| Scientists | 2 | 7% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 22% |
| Student > Master | 11 | 15% |
| Other | 6 | 8% |
| Student > Ph. D. Student | 4 | 5% |
| Student > Postgraduate | 3 | 4% |
| Other | 10 | 14% |
| Unknown | 24 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Immunology and Microbiology | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Unspecified | 2 | 3% |
| Other | 8 | 11% |
| Unknown | 30 | 41% |
Attention Score in Context
This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 November 2020.
All research outputs
#1,383,829
of 25,711,518 outputs
Outputs from Emerging Infectious Diseases
#1,563
of 9,783 outputs
Outputs of similar age
#27,527
of 336,943 outputs
Outputs of similar age from Emerging Infectious Diseases
#26
of 153 outputs
Altmetric has tracked 25,711,518 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 9,783 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 45.7. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,943 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 153 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.